JPRN-jRCTs051180110已完成2 期
Evaluation of the efficacy of Ledipasvir and Sofosbuvir in children with genotype 1 hepatitis C virus infection
Tajiri Hitoshi0 个研究点目标入组 2 人开始时间: 2019年3月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2
研究概览
简要总结
Combination therapy of ledipasvir and sofosbuvir was safe and effective in the two cases.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12age 至 18age（—）
- 性别
- All
入选标准
- •1. Patients who are visiting the department of Pediatrics or being admitted in our institute.
- •2. Patients with age 12 and 18 years at the agreement acquisition.
- •3. HCV genotype-1 infection.
- •4. Written informed consent after adequate explanation and acceptance.
排除标准
- •1. Patients with a suspicion of cirrhosis by blood examination or imaging studies.
- •2. Patients who is diagnosed as liver cirrhosis by pathological examination.
- •3. Patients with hepatocellular carcinoma.
- •4. Patients with poor adherence of medicine.
- •5. Patients who have any underlying disorders which can be affected by the treatment.
- •6. Patients who are assessed to be ineligible for this study by the principle investigator.
研究者
相似试验
尚未招募
不适用
Efficacy and safety of ledipasvir and sofosbuvir in patients with chronic hepatitis CPatients with chronic hepatitis C virus infectionJPRN-UMIN000018561Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology2,000
已完成
不适用
Effectiveness and safety of ledipasvir and sofosbuvir for patients infected with HCV genotype 1 in clinical practicesChronic hepatitis C genotype 1JPRN-UMIN000024007Kyushu University1,000
招募中
不适用
Evaluation of the efficacy of sofosbuvir and ledipasvir for Japanese hepatitis C patients: a prospective study in real-life settings.chronic hepatitis CJPRN-UMIN000019468Toranomon Hospital100
已完成
不适用
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of TenofovirHepatitis C and HIV CoinfectionNCT02588287University of Colorado, Denver14
已完成
4 期
Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)HIV CoinfectionHepatitis CNCT03126370University of Colorado, Denver10